Skip to content

Italian National Study on the Critically Ill Liver Transplant Patient With an Infection

Italian National Multicenter Study on Infections in the Critically Ill Liver Transplant Recipient

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03363646
Acronym
INFE-OLT
Enrollment
200
Registered
2017-12-06
Start date
2018-07-01
Completion date
2019-08-30
Last updated
2018-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Intensive Care Unit, Liver Transplantation, Sepsis

Brief summary

Despite major advances, infections remain one of the major causes of morbidity and mortality in patients undergoing orthotopic liver transplantation (OLT). Furthermore, data on the epidemiology, severity, and type of post-OLT infections nowadays available come from dated, monocentric, retrospective series. Finally, there is no available data focused on the critical OLT patient admitted to the Intensive Care Unit (ICU). Therefore this study was conceived (1) to describe incidence, severity, epidemiology and outcomes of infections recorded in OLT patients in the ICU (first or re-admission ); (2) to identify possible risk factors and (3) to report the type of the involved microorganism with their antibiotic sensitivity pattern

Detailed description

The study will record clinical, epidemiological and microbiological data from the clinical files of OLT patients admitted at italian ICUs

Interventions

None listed

Sponsors

Azienda Ospedaliero, Universitaria Pisana
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

1. Age\> 18 aa 2. Sex: Both 3. written consent to participate in the study 4. having been undergone to OLT in the 10 years prior to enrollment 5. Infection diagnosis (any type, any localization, any agent) 6. Being admitted in the ICU

Exclusion criteria

1. Death within 72 hours of admission 2. Withdrawal of consent \-

Design outcomes

Primary

MeasureTime frameDescription
Clinical18 monthsnumber and severity of infectious episodes
microbiological18 monthsdescribe the type of infectious agents

Secondary

MeasureTime frameDescription
Resistance18 monthsantibiotic resistance patters of the isolates

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026